bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.07.16.665106

Prediction of cellular morphology change under perturbations with transcriptome-guided diffusion model

Abstract

Investigating the cell morphology change after perturbations with high-throughput image-based profiling is of growing interest, considering its wide applications in phenotypic drug discovery, including MOA (Mechanism Of Action) prediction, compound bioactivity prediction, and drug repurposing. However, the vast space of chemical and genetic perturbations makes it infeasible to fully explore all the potential perturbations with image-profiling technologies. Consequently, developing a powerful in-silico method to simulate high-fidelity cell morphological response under perturbations can reduce the experiment costs and accelerate drug discovery. Motivated by this, we proposed MorphDiff, a transcriptome-guided latent diffusion model for accurately predicting the cell morphology response to perturbations. We applied MorphDiff to two large-scale datasets, including one drug perturbation and one genetic perturbation cell morphology dataset covering thousands of diverse perturbations. Extensive benchmarking and comparison with baseline methods show the remarkable accuracy and fidelity of MorphDiff in predicting cell morphological changes under unseen perturbations. Furthermore, we explored the utilities of MorphDiff in identifying and retrieving the MOAs of drugs, which is a crucial application in phenotypic drug discovery. With the designed pipeline for MOA retrieval, we demonstrated MorphDiffs capability to boost the retrieval of the drugs MOAs (Mechanism Of Actions) by generating realistic cell morphology profiles. The average MOA retrieval accuracy of MorphDiff-generated morphology is comparable with that of the ground truth cell morphology, and consistently outperforms the baseline method and gene expressionbased retrieval by 29.1% and 9.7% respectively. We also validated that complementary information provided by cell morphology generated by MorphDiff can help discover drugs with dissimilar structures but the same MOAs. In summary, with its strong capabilities in generating high-fidelity cell morphology on unseen perturbations, we envision MorphDiff as a powerful tool in phenotypic drug discovery by accelerating the phenotypic screening of vast perturbation space and improving MOA identification.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wang, X., Fan, Y., Guo, Y., Fu, C., Lee, K., Dallakyan, K., Li, Y., Yin, Q., Song, L.. 2025-07-16. Prediction of cellular morphology change under perturbations with transcriptome-guided diffusion model. https://doi.org/10.1101/2025.07.16.665106

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗

Matrix Gla Protein deficiency reveals a previously unrecognized mucosal calcification in the mouse airways

Tracheal calcification is a common finding that is considered to have limited clinical significance when detected most often in elderly individuals. Despite its frequent occurrence, the cellular and molecular mechanisms at the origin of tracheal calcification remain largely unexplored. In this context, we aimed to characterize the development of tracheal calcification, and to determine the role of matrix Gla protein (MGP), a major inhibitor of ectopic calcification whose genetic or pharmacologic deficiency is associated with premature tracheal calcification in humans. We found that wild-type mice undergo an unexpected early physiologic calcification of the tracheal cartilage rings beginning around one month after birth. This calcification progresses in a dynamic rostro-caudal sequence through a process involving terminal differentiation of tracheal chondrocytes. These findings challenge the prevailing view that tracheal cartilage is a permanent hyaline cartilage and instead reveals an early and highly organized physiologic calcification process. Furthermore, our findings further identify MGP as a key regulator of calcification within the respiratory tract. Indeed, MGP deficiency not only markedly accelerates tracheal cartilage calcification through a similar pattern and mechanism but also induces a previously unrecognized calcification of the tracheal mucosa, a lesion absent in wild-type mice. These alterations could partly explain the respiratory manifestations observed in MGP-deficient patients having Keutel syndrome, which include dyspnea, cough, stridor, and recurrent infections, symptoms previously being mainly attributed to calcification of the tracheal cartilage rings.

cell biology↗